Use of two-dimensional gel electrophoresis to measure changes in synovial fluid proteins from patients with rheumatoid arthritis treated with antibody to CD4.
Synovial fluid proteins from microliter volumes of synovial fluid were resolved by two-dimensional polyacrylamide gel electrophoresis and detected by silver staining to investigate the feasibility of using two-dimensional (2D) electrophoresis in the clinical research setting and provide global disease information of disease progression. Several hundred proteins could be resolved as spots, many of which displayed the characteristic pattern of plasma-derived glycoproteins. The lowest level of detection was approximately 0.2 ng from a total of 50 microg of protein loaded. Most of the proteins could be identified on the basis of pI and molecular weight when compared with plasma protein maps on the World Wide Web. Unknown proteins were characterized by mass spectrometry of tryptic digests and by comparison with peptide databases. Synovial fluids from patients with rheumatoid arthritis were analyzed using this technique. Each subject received a fixed dose of antibody to CD4 as part of a phase II clinical trial to determine the efficacy of this immunosuppressive treatment in modifying disease activity. Synovial fluid was removed at day 0, followed by administration of antibody. Subsequent removal of synovial fluid and additional administration of antibody were carried out at different times thereafter. Changes in levels of acute-phase proteins were quantified by densitometry of silver-stained 2D polyacrylamide gels. Other parameters of disease progression such as serum C-reactive protein and physician's global assessment of clinical condition were used for comparison. In this way, changes in acute-phase proteins towards normal levels, as measured by 2D polyacrylamide gel electrophoresis, could be correlated with clinical improvement and conventional clinical chemistry measurements. Thus, the system can be used for quantitative analysis of protein expression in sites of autoimmune disease activity such as the synovial fluid of rheumatoid arthritis patients.
Smith
M A
MA
Immunopathology, Glaxo Wellcome Research and Development plc, Stevenage, Herts SG1 2NY, United Kingdom. MAS47690@GlaxoWellcome.co.uk
Bains
S K
SK
Betts
J C
JC
Choy
E H
EH
Zanders
E D
ED
D000209:Acute-Phase Proteins / Q000032:analysis; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000378:metabolism* / Q000628:therapy; D015704:CD4 Antigens / Q000276:immunology*; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods; D005240:Feasibility Studies; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods; D011506:Proteins / Q000032:analysis*; D013582:Synovial Fluid / Q000276:immunology / Q000378:metabolism*
C416007:4162W94 IgG1; D000209:Acute-Phase Proteins; D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D007136:Immunoglobulins; D011506:Proteins